お知らせ • Jul 21
Samsung Biologics Co.,Ltd. (KOSE:A207940) entered into a transaction agreement to acquire PolyPeptide Group AG (SWX:PPGN) from Draupnir Holding B.V. and others for CHF 1.5 billion. Samsung Biologics Co.,Ltd. (KOSE:A207940) entered into a transaction agreement to acquire PolyPeptide Group AG (SWX:PPGN) from Draupnir Holding B.V. and others for CHF 1.5 billion on July 17, 2026. Under the terms of the agreement, Samsung Biologics agreed to make an all-cash public tender offer to acquire all publicly held registered shares of PolyPeptide for CHF 44.31 in cash per share. The Offer values PolyPeptide's equity at approximately CHF 1.46 billion. The transaction aims to provide PolyPeptide with the resources, investment capacity and strategic platform to pursue the next phase of its growth and innovation. Alongside Samsung Biologics’ global manufacturing scale and track record of operational excellence, PolyPeptide will also benefit from an aligned customer footprint. Draupnir Holding B.V. owning a stake of approximately 56.3% stake has been in support of the strategic review process and has committed to tender all of its shares into the offer. Once the offer has been successfully completed, Samsung Biologics intends to pursue a squeeze-out of any remaining minority shares and to delist PolyPeptide from the SIX Swiss Exchange. Upon completion, PolyPeptide will operate as a wholly owned subsidiary of Samsung Biologics.
The transaction is subject to approval by the shareholders of PolyPeptide Group AG, minimum acceptance threshold of 66?%, applicable regulatory approvals, and other conditions. The Board of Directors of PolyPeptide Group AG formed a special committee for the transaction. The deal has been unanimously approved by the special committee of board of directors of PolyPeptide Group AG and recommends that PolyPeptide shareholders accept the tender offer. The tender offer is expected to be launched by the end of August 2026 by publication of the formal offer prospectus and will remain open for a minimum of twenty trading days on the SIX Swiss Exchange. The transaction is expected to be completed towards the end of 2026.
JP Morgan Korea acted as exclusive financial advisor to Samsung Biologics Co.,Ltd. Ernst & Young, Korea acted as accountant to Samsung Biologics Co.,Ltd. O'Melveny & Myers LLP, Seoul office acted as legal advisor to Samsung Biologics Co.,Ltd. Schellenberg Wittmer acted as legal advisor to Samsung Biologics Co.,Ltd. IFBC AG acted as fairness opinion provider to PolyPeptide Group AG. Morgan Stanley & Co. International plc acted as exclusive financial advisor to PolyPeptide Group AG. Homburger AG acted as legal advisor to PolyPeptide Group AG. お知らせ • Mar 18
PolyPeptide Group AG, Annual General Meeting, Apr 08, 2026 PolyPeptide Group AG, Annual General Meeting, Apr 08, 2026, at 16:00 W. Europe Standard Time. お知らせ • Sep 23
PolyPeptide Group AG Achieves Significant Milestone in Malmo Expansion Project PolyPeptide Group AG announced the successful delivery and installation of pre-built modules at its Malmo, Sweden facility. This marks a key milestone in the company's modular expansion project at the site, which aims to double its solid-phase peptide synthesis (SPPS) capacity. The expansion, first announced in January 2025, is a central component of PolyPeptide's mid-term strategy to meet rising global demand for peptide production. The EUR 100 million metabolic program investment was largely funded by a large pharmaceutical partner and will create around 100 permanent new positions. It is anticipated that the expansion will be significantly faster than previous engineering projects due to the modular construction approach. Following installation, the modules will now undergo mechanical completion and automation, followed by qualification and commissioning. Key Project Highlights: Accelerated timeline: The Malmo capacity expansion is on track to be faster than previous engineering expansions due to the modular approach. Strategic partnership: The EUR 100 million investment was largely funded by a largest pharmaceutical player. Modular construction: Pre-built manufacturing modules installed with proprietary manufacturing systems, delivered and installed on-site. Operational continuity: Existing manufacturing operations remain uninterrupted. Advanced technology: Integrated engineering, automation, and process control. Quality assurance: All modules built to meet stringent pharmaceutical GMP standards. The additional capacity will primarily support one of PolyPeptide's large commercial agreements, contributing to its long-term growth initiatives and capital deployment strategy. As communicated in its mid-term outlook, the company expects over the mid-term horizon and on average, capital expenditures of 15-20% of revenue to ensure capacity beyond 2028. お知らせ • Apr 11
Polypeptide Group Ag Appoints Jo Lecouilliard as Independent Director PolyPeptide Group AG announced the appointment of Jo LeCouilliard as Independent Director. Buy Or Sell Opportunity • Apr 03
Now 23% undervalued Over the last 90 days, the stock has risen 63% to CHF28.35. The fair value is estimated to be CHF36.60, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 8.8% in a year. Earnings are forecast to grow by 77% in the next year. 
